Friday, December 8, 2023
WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.
Disclosures for additional planners can be found here.
President
European Atherosclerosis Society
Professor of Public Health and Honorary Consultant Cardiologist
Director, Imperial Centre for Cardiovascular Disease Prevention
Deputy Director
Imperial Clinical Trials Unit
Head of Commercial Trials
Imperial College London
London, United Kingdom
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
processing....
Posted: 27/12/2022
This educational activity is intended for an international audience of non-US cardiologists, primary care physicians and nephrologists.
The goal of this activity is for learners to be better able to incorporate new data on lipid-lowering therapies into the clinical management of dyslipidemia.
Upon completion of this activity, participants will:
The goal of this activity is for learners to be better able to incorporate new data on lipid-lowering therapies into the clinical management of dyslipidemia.
Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.
